A randomized, double-blind, placebocontrolled MRI study of anti–herpes virus therapy in MS A randomized, double-blind, placebocontrolled MRI study of anti–herpes virus therapy in MS2018-01-17T17:01:19-05:00
A Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis A Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis2018-01-17T17:01:13-05:00
Polyneuropathy associated with interferon beta treatment in patients with multiple sclerosis Polyneuropathy associated with interferon beta treatment in patients with multiple sclerosis2018-01-17T17:01:07-05:00
Disease modifying therapies in multiple sclerosis Disease modifying therapies in multiple sclerosis2018-01-17T17:01:01-05:00
Problems with UK government’s risk sharing scheme for assessing drugs for multiple sclerosis Problems with UK government’s risk sharing scheme for assessing drugs for multiple sclerosis2018-01-17T17:00:50-05:00
Statins for the treatment of multiple sclerosis: cautious hope Statins for the treatment of multiple sclerosis: cautious hope2018-01-17T17:00:50-05:00
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis2018-01-17T17:00:50-05:00
Natalizumab and Progressive Multifocal Leukoencephalopathy Natalizumab and Progressive Multifocal Leukoencephalopathy2018-01-17T17:00:38-05:00
Intravenous immunoglobulin in neurological disease: a specialist review Intravenous immunoglobulin in neurological disease: a specialist review2018-01-17T17:00:38-05:00
